Contact:
4008465777
-
About Us
News & Events
-
12-30
Tonghua Dongbao: Phase I clinical trial on the ultra-rapid-acting insulin lispro injection meets primary endpoint
Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") has recently completed a Phase I pivotal clinical trial on the BC Lispro (THDB0206), an ultra-rapid-acting insulin lispro ...
-
12-23
Tonghua Dongbao: Clinical trial application for THDBH151 Tablets approved
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (“Dongbao Zixing”), a wholly-owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) rec...
-
12-07
Tonghua Dongbao and Kexing Biopharm team up to fast-track product expansion abroad
On December 6, 2022, Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao” or the “Company”) and Kexing Biopharm Co., Ltd. (“Kexing Biopharm”) signed the Exclusive License Agreement for Li...
-
11-15
Tonghua Dongbao receives the registration approval for premixed insulin aspart injections
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) received the Pharmaceutical Product Registration Certificate from the National Medical Products Administrati...
-
10-31
Tonghua Dongbao: Q3 performance improves QoQ, with insulin analog sales doubling
Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as “Tonghua Dongbao” or the “Company”) released its quarterly report for Q3 2022 on October 30. According to t...
-
10-12
Tonghua Dongbao obtains the Pharmaceutical Product Registration Certificate for repaglinide tablets
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) received the Pharmaceutical Product Registration Certificate for repaglinide tablets issued by the National ...